-
23 February 2016 | Strategia Therapeutics Spins Out SOLA Biosciences to Commercialize Tapboost® Technology
Headquartered in Boston, SOLA focuses on Tapboost® technology and globally collaborates with various pharmaceutical companies and researchers.
-
19 February 2016 | Strategia Therapeutics Initiates a Phase 1 Clinical Trial of the Anti-cancer Agent “FF-10502″ For FUJIFILM in Patients with Advanced Cancers
Strategia, a primary global strategic drug development provider for FUJIFILM Pharmaceuticals U.S.A., Inc. (FPHU), has initiated a Phase 1 clinical trial of FUJIFILM’s anti-cancer agent FF-10502 in the United States in patients with advanced solid tumor cancers and lymphoma.
-
15 January 2016 | Strategia Therapeutics Initiates a Phase 1 Clinical Trial of the Radioimmunotherapeutic “FF-21101″ For FUJIFILM in Patients with Advanced Cancers
The trial is being performed at The University of Texas MD Anderson Cancer Center with Vivek Subbiah, M.D., as the Principal Investigator. Dr. Subbiah is an Assistant Professor in the Department of Investigational Therapeutics and an expert in Phase 1 cancer clinical research of molecularly-targeted radiopharmaceuticals.
-
24 December 2015 | Strategia Therapeutics Announces Progress in a Phase 1 Clinical Trial of the Anti-cancer Agent “FF-10501-01” for FUJIFILM in Patients with Advanced Hematologic Malignancies
The emerging results reveal that, in the Phase 1 dose escalation phase thus far (5 dose cohorts), FF-10501-01 has been highly tolerable and has demonstrated promising preliminary efficacy.
-
10 August 2015 | New Website Launch
Strategia Therapeutics Inc. today announced the launch of a new, redesigned version of its website.
-
20 July 2015 | Oncology/Hematology Medical Advisory Board
Strategia Therapeutics Forms Oncology/Hematology Medical Advisory Board
-
22 April 2015 | Phase 1/2a Clinical Trial of E6201
Strategia Therapeutics Initiates a Phase 1/2a Clinical Trial of the Anti-cancer Agent E6201 in Patients with Advanced Hematologic Malignancies
-
08 April 2015 | Company Name Change
Boston Strategic Corporation Announces Name To Strategia Therapeutics, Inc.
-
16 December 2014 | Risk-Sharing Agreement with MDACC
Boston Strategics Enters into an Innovative Risk-Sharing Agreement with the MD Anderson Cancer Center to Conduct a Phase 1/2a Clinical Trial of E6201 in Patients with Advanced Hematologic Malignancies Including Acute Myeloid Leukemia
-
14 October 2014 | Key Agreement With Molecular Response
Boston Strategics Corporation Announces Key Agreement In Translational Oncology With Molecular Response
-
29 August 2014 | P1 Clinical Trial of FF-10501 Initiated
Boston Strategics Corporation Initiates a Phase 1 Clinical Trial of the Anti-cancer Agent “FF-10501” for FUJIFILM in Patients with Advanced Hematologic Malignancies
-
30 June 2014 | Licensing Deal with Eisai
Boston Strategics Corporation Announces Licensing Deal with Eisai Co., Ltd.
-
26 November 2013 | Partnership with FUJIFILM
Boston Strategics Announces Oncology Drug Development Partnership with FUJIFILM Pharmaceuticals U.S.A.
-
25 July 2013 | Alliance with MDACC
Boston Strategics Announces Strategic Alliance with UT MD Anderson for Oncology Drug Development
